Thorsten Graef

4.5k total citations
61 papers, 2.0k citations indexed

About

Thorsten Graef is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Thorsten Graef has authored 61 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 26 papers in Molecular Biology and 21 papers in Genetics. Recurrent topics in Thorsten Graef's work include Multiple Myeloma Research and Treatments (26 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Protein Degradation and Inhibitors (16 papers). Thorsten Graef is often cited by papers focused on Multiple Myeloma Research and Treatments (26 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Protein Degradation and Inhibitors (16 papers). Thorsten Graef collaborates with scholars based in United States, Germany and France. Thorsten Graef's co-authors include Peter Parham, Laurent Abi-Rached, Achim K. Moesta, Paul J. Norman, Rainer Haas, Lisbeth A. Guethlein, Anastazia M. Older Aguilar, Guido Kobbe, Meletios Α. Dimopoulos and Roland Fenk and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Thorsten Graef

59 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thorsten Graef United States	23	876	671	651	627	538	61	2.0k
Andrés Jerez Spain	17	793 0.9×	639 1.0×	527 0.8×	593 0.9×	210 0.4×	60	1.6k
Mireia Camós Spain	22	576 0.7×	502 0.7×	329 0.5×	500 0.8×	547 1.0×	57	1.8k
Coralie Bélanger France	21	1.4k 1.5×	726 1.1×	246 0.4×	586 0.9×	919 1.7×	44	2.2k
James A. L. Fenton United Kingdom	16	402 0.5×	522 0.8×	486 0.7×	695 1.1×	320 0.6×	31	1.4k
Ana Rasillo Spain	20	992 1.1×	560 0.8×	259 0.4×	597 1.0×	302 0.6×	22	1.5k
Christine Arnoulet France	28	1.6k 1.8×	885 1.3×	809 1.2×	702 1.1×	624 1.2×	69	2.6k
Alessandra Pucciarini Italy	14	359 0.4×	475 0.7×	345 0.5×	413 0.7×	413 0.8×	19	1.4k
Gösta Gahrton Sweden	5	1.2k 1.4×	925 1.4×	367 0.6×	616 1.0×	708 1.3×	7	1.8k
Nikolaos Anagnostopoulos Greece	17	753 0.9×	513 0.8×	221 0.3×	576 0.9×	474 0.9×	41	1.3k
L Richter United States	16	854 1.0×	826 1.2×	262 0.4×	355 0.6×	753 1.4×	27	1.8k

Countries citing papers authored by Thorsten Graef

Since Specialization

Citations

This map shows the geographic impact of Thorsten Graef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thorsten Graef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thorsten Graef more than expected).

Fields of papers citing papers by Thorsten Graef

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thorsten Graef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thorsten Graef. The network helps show where Thorsten Graef may publish in the future.

Co-authorship network of co-authors of Thorsten Graef

This figure shows the co-authorship network connecting the top 25 collaborators of Thorsten Graef. A scholar is included among the top collaborators of Thorsten Graef based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thorsten Graef. Thorsten Graef is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maakaron, Joseph, Dipenkumar Modi, Matthew Mei, et al.. (2024). Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study. Blood. 144(Supplement 1). 3052–3052. 2 indexed citations

Khanal, Rashmi, Amitkumar Mehta, Joseph Maly, et al.. (2023). AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.. Journal of Clinical Oncology. 41(16_suppl). 7529–7529. 3 indexed citations

Hong, David S., Drew Rasco, Michael H. Veeder, et al.. (2019). A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology. 97(2). 102–111. 66 indexed citations

O’Brien, Susan, Peter Hillmen, Steven Coutré, et al.. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 648–657.e15. 63 indexed citations

Buske, Christian, Shalal Sadullah, Efstathios Kastritis, et al.. (2018). Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. The Lancet Haematology. 5(7). e299–e309. 28 indexed citations

Chari, Ajai, Saulius Girnius, Saurabh Chhabra, et al.. (2017). Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 130. 3111–3111. 2 indexed citations

Ribrag, Vincent, Won Seog Kim, Réda Bouabdallah, et al.. (2017). Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 102(5). 903–909. 71 indexed citations

Vey, Norbert, Thomas Prébet, Claire Thalamas, et al.. (2016). Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leukemia & lymphoma. 58(8). 1880–1886. 15 indexed citations

Siegel, David S., Meletios Α. Dimopoulos, Sundar Jagannath, et al.. (2016). VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 16(6). 329–334.e1. 23 indexed citations

10.

Evens, Andrew M., Sriram Balasubramanian, Julie M. Vose, et al.. (2015). A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clinical Cancer Research. 22(5). 1059–1066. 73 indexed citations

11.

Dimopoulos, Meletios Α., David S. Siegel, Sagar Lonial, et al.. (2013). Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet Oncology. 14(11). 1129–1140. 181 indexed citations

12.

Weber, Donna M., Thorsten Graef, Mohamad A. Hussein, et al.. (2012). Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 12(5). 319–324. 37 indexed citations

13.

Hilton, Hugo G., Luca Vago, Anastazia M. Older Aguilar, et al.. (2012). Mutation at Positively Selected Positions in the Binding Site for HLA-C Shows That KIR2DL1 Is a More Refined but Less Adaptable NK Cell Receptor Than KIR2DL3. The Journal of Immunology. 189(3). 1418–1430. 69 indexed citations

14.

Bruns, Ingmar, Frank Neumann, Johannes Fischer, et al.. (2007). Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 21(3). 494–504. 113 indexed citations

15.

Graef, Thorsten, Roland Fenk, Fabian Zohren, et al.. (2007). Prognostic factors for patients with acute myeloid leukaemia or high‐risk myelodysplastic syndromes undergoing myeloablative or non‐myeloablative allogeneic blood stem cell transplantation. Hematological Oncology. 25(4). 170–177. 6 indexed citations

16.

Fenk, Roland, Mark Michael, Fabian Zohren, et al.. (2007). Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leukemia & lymphoma. 48(12). 2345–2351. 31 indexed citations

17.

Fenk, Roland, Ulrich Steidl, Ingmar Bruns, et al.. (2006). Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Experimental Hematology. 34(10). 1296–1302. 20 indexed citations

18.

Graef, Thorsten, et al.. (2006). Use of RNA interference to inhibit integrin subunit αV-mediated angiogenesis. Angiogenesis. 8(4). 361–372. 9 indexed citations

19.

Neumann, Frank, Thorsten Graef, Ulrich Steidl, et al.. (2005). Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplantation. 35(11). 1089–1093. 64 indexed citations

20.

Kobbe, Guido, Roland Fenk, Frank Neumann, et al.. (2004). Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy. 6(6). 533–542. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact